Six point indications for an extension. The launch on market will be reported by European Medicine Agency (EMA).

1. Izba   (travoprost) in the treatment of ocular hypertension or glaucoma, pediatric in patients 3 to 18 years of age.

2.komboglyze   (saxagliptin and metformin hydrochloride) in type 2 diabetes in adults in combination with other treatments for diabetes in patients who are not satisfactorily controlled.

3.onglyza   (saxagliptin) in type 2 diabetes: the adulte  monotherapy when metformin is not appropriate, or in combination with other treatments for diabetes in patients with inadequate glycaemic control.

4. renvela   (sevelamer carbonate) in the control of hyperphosphatemia in patients from the age of 6 and having a surface area greater than 0.75 m2 atteints in chronic renal failure.

5. sevelamer carbonate (carbonate zentiva   sevelamer) in the control of hyperphosphatemia in patients from the age of 6 and having a surface area greater than 0.75 m2 atteints in chronic renal failure.

6. zykadia   (ceritinib) as monotherapy in the first-line treatment of non-small cell lung cancer ALK+.http/www.ansm.fr